Aster DM Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ASTERDM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aster DM Healthcare reported its Q1 FY26 results with consolidated revenue from operations rising about 7.6% year-on-year to INR 1,077.87 crores (from INR 1,001.87 crores). Profit after tax from continuing operations grew roughly 15.5% to INR 93.56 crores (from INR 81.00 crores), with EPS from continuing operations at INR 1.67 versus INR 1.49 a year ago. Standalone revenue rose about 8.4% to INR 613.04 crores, but standalone PAT comparison is skewed by last year's one-time gain of around INR 5,148 crores from the GCC business separation. The statutory auditor Deloitte Haskins & Sells issued an unmodified (clean) opinion. Other updates include a final dividend of INR 1 per share (record date August 28, 2025), completion of the preferential allotment of 1.86 crore shares to BCP Asia and Centella Mauritius, and Board approval to buy Block-D assets of Aster Whitefield Hospital from wholly owned subsidiary AMHPL for up to INR 80 crores.
Steady revenue and profit growth from core (continuing) hospital operations, backed by a clean audit, is a positive signal for shareholders. Investors should note the INR 4.39 crore exceptional charge for merger and acquisition advisory fees and the INR 80 crore related-party asset purchase from AMHPL, both of which are flagged for transparency.